NK Cell Therapy With BHV-1100

Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
25 patients (estimated)
Sponsors
Biohaven Pharmaceuticals, Inc.
Tags
Natural Killer (NK) Cells, CD38
Trial Type
Treatment
Last Update
1 week ago
SparkCures ID
1110
NCT Identifier
NCT04634435

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.